Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.55
IMGN's Cash-to-Debt is ranked lower than
77% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. IMGN: 1.55 )
Ranked among companies with meaningful Cash-to-Debt only.
IMGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39  Med: No Debt Max: 50356.33
Current: 1.55
0.39
50356.33
Equity-to-Asset -0.96
IMGN's Equity-to-Asset is ranked lower than
97% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. IMGN: -0.96 )
Ranked among companies with meaningful Equity-to-Asset only.
IMGN' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.03  Med: 0.74 Max: 0.96
Current: -0.96
-1.03
0.96
Debt-to-Equity -0.56
IMGN's Debt-to-Equity is ranked lower than
99.99% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. IMGN: -0.56 )
Ranked among companies with meaningful Debt-to-Equity only.
IMGN' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.17  Med: 0.03 Max: 1.53
Current: -0.56
-1.17
1.53
Piotroski F-Score: 3
Altman Z-Score: -6.54
Beneish M-Score: -2.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -96.06
IMGN's Operating Margin % is ranked lower than
59% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. IMGN: -96.06 )
Ranked among companies with meaningful Operating Margin % only.
IMGN' s Operating Margin % Range Over the Past 10 Years
Min: -447.86  Med: -116.56 Max: -58.16
Current: -96.06
-447.86
-58.16
Net Margin % -118.05
IMGN's Net Margin % is ranked lower than
61% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. IMGN: -118.05 )
Ranked among companies with meaningful Net Margin % only.
IMGN' s Net Margin % Range Over the Past 10 Years
Min: -448.24  Med: -116.63 Max: -49.69
Current: -118.05
-448.24
-49.69
ROA % -61.44
IMGN's ROA % is ranked lower than
79% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. IMGN: -61.44 )
Ranked among companies with meaningful ROA % only.
IMGN' s ROA % Range Over the Past 10 Years
Min: -61.44  Med: -35.78 Max: -17.46
Current: -61.44
-61.44
-17.46
ROC (Joel Greenblatt) % -540.80
IMGN's ROC (Joel Greenblatt) % is ranked lower than
58% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. IMGN: -540.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IMGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -649.63  Med: -323.04 Max: -150
Current: -540.8
-649.63
-150
3-Year Revenue Growth Rate 67.10
IMGN's 3-Year Revenue Growth Rate is ranked higher than
91% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. IMGN: 67.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IMGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -47.7  Med: -1.1 Max: 115.4
Current: 67.1
-47.7
115.4
3-Year EBITDA Growth Rate -13.40
IMGN's 3-Year EBITDA Growth Rate is ranked lower than
69% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. IMGN: -13.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IMGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -72.2  Med: 0.1 Max: 296.3
Current: -13.4
-72.2
296.3
3-Year EPS without NRI Growth Rate -9.30
IMGN's 3-Year EPS without NRI Growth Rate is ranked lower than
60% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. IMGN: -9.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IMGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -75.7  Med: -0.4 Max: 263.4
Current: -9.3
-75.7
263.4
GuruFocus has detected 3 Warning Signs with Immunogen Inc $IMGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IMGN's 30-Y Financials

Financials (Next Earnings Date: 2017-10-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

IMGN Guru Trades in Q3 2016

Jim Simons 2,503,340 sh (+27.26%)
Ken Fisher 253,701 sh (unchged)
PRIMECAP Management 9,619,122 sh (-4.89%)
Paul Tudor Jones 30,249 sh (-52.21%)
» More
Q4 2016

IMGN Guru Trades in Q4 2016

Paul Tudor Jones 32,880 sh (+8.70%)
Jim Simons 2,481,740 sh (-0.86%)
Ken Fisher 248,576 sh (-2.02%)
PRIMECAP Management 5,052,943 sh (-47.47%)
» More
Q1 2017

IMGN Guru Trades in Q1 2017

Ken Fisher 253,676 sh (+2.05%)
PRIMECAP Management 3,966,000 sh (-21.51%)
Paul Tudor Jones 24,493 sh (-25.51%)
Jim Simons 1,477,946 sh (-40.45%)
» More
Q2 2017

IMGN Guru Trades in Q2 2017

John Paulson 229,222 sh (New)
Ken Fisher 256,206 sh (+1.00%)
Paul Tudor Jones Sold Out
PRIMECAP Management 3,882,500 sh (-2.11%)
Jim Simons 722,340 sh (-51.13%)
» More
» Details

Insider Trades

Latest Guru Trades with IMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 1.00%$2.89 - $7.22 $ 6.5545%256,206
John Paulson 2017-06-30 New Buy0.02%$2.89 - $7.22 $ 6.5544%229,222
Ken Fisher 2017-03-31 Add 2.05%$2.08 - $3.89 $ 6.55124%253,676
Ken Fisher 2016-12-31 Reduce -2.02%$1.56 - $2.67 $ 6.55226%248,576
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CYTK, NAS:RVNC, NAS:GTHX, NAS:PTCT, NAS:RETA, NAS:AKBA, NAS:ANIK, NAS:NTLA, NAS:VNDA, NAS:TGTX, NAS:LJPC, NAS:AKAO, NAS:AMAG, NAS:ABEO, NAS:BOLD, NAS:ALDR, NAS:ACRS, NAS:ADRO, NAS:PRTK, NAS:DOVA » details
Traded in other countries:IMU.Germany,
Headquarter Location:USA
Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products.

Immunogen is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.

Top Ranked Articles about Immunogen Inc

Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products
Despite Decline in Global Markets, Several Stocks Are Jumping Stocks move higher in Friday's pre-market trading
Wall Street is trading in red after the Federal Reserve kept rates intact at 1% and 1.25%. A rate hike is expected at the end of the year and three more next year. It is also expected to start the process of selling bonds for the month of September. Read more...

Ratios

vs
industry
vs
history
PS Ratio 6.40
IMGN's PS Ratio is ranked higher than
53% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. IMGN: 6.40 )
Ranked among companies with meaningful PS Ratio only.
IMGN' s PS Ratio Range Over the Past 10 Years
Min: 2.67  Med: 14.89 Max: 97.63
Current: 6.4
2.67
97.63
EV-to-EBIT -8.05
IMGN's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. IMGN: -8.05 )
Ranked among companies with meaningful EV-to-EBIT only.
IMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -44  Med: -9.1 Max: -0.3
Current: -8.05
-44
-0.3
EV-to-EBITDA -8.68
IMGN's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. IMGN: -8.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -51.8  Med: -10.05 Max: -0.3
Current: -8.68
-51.8
-0.3
EV-to-Revenue 7.66
IMGN's EV-to-Revenue is ranked higher than
56% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. IMGN: 7.66 )
Ranked among companies with meaningful EV-to-Revenue only.
IMGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 12.6 Max: 85.5
Current: 7.66
0.8
85.5
Current Ratio 2.40
IMGN's Current Ratio is ranked lower than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. IMGN: 2.40 )
Ranked among companies with meaningful Current Ratio only.
IMGN' s Current Ratio Range Over the Past 10 Years
Min: 0.51  Med: 7.29 Max: 60.86
Current: 2.4
0.51
60.86
Quick Ratio 2.34
IMGN's Quick Ratio is ranked lower than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. IMGN: 2.34 )
Ranked among companies with meaningful Quick Ratio only.
IMGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.51  Med: 7.25 Max: 60.86
Current: 2.34
0.51
60.86
Days Sales Outstanding 4.20
IMGN's Days Sales Outstanding is ranked higher than
82% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. IMGN: 4.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.88  Med: 19.78 Max: 88.26
Current: 4.2
2.88
88.26

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.60
IMGN's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. IMGN: -3.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -87.6  Med: -12.85 Max: -0.7
Current: -3.6
-87.6
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.43
IMGN's Price-to-Median-PS-Value is ranked higher than
68% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. IMGN: 0.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IMGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 2.05 Max: 10.58
Current: 0.43
0.22
10.58
Earnings Yield (Greenblatt) % -12.44
IMGN's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. IMGN: -12.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IMGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -321  Med: -11 Max: -2.3
Current: -12.44
-321
-2.3

More Statistics

Revenue (TTM) (Mil) $89.03
EPS (TTM) $ -1.21
Beta2.49
Short Percentage of Float27.99%
52-Week Range $1.51 - 8.84
Shares Outstanding (Mil)112.22

Analyst Estimate

Dec16 Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 60 119 12 108 318
EPS ($) -1.55 -0.84 -1.58 -1.01 0.69
EPS without NRI ($) -1.55 -0.84 -1.58 -1.01 0.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IMGN

Headlines

Articles On GuruFocus.com
Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Aug 29 2017 
Despite Decline in Global Markets, Several Stocks Are Jumping Jul 28 2017 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Gulf Resources (GURE) Soars on Natural Gas Discovery, ImmunoGen (IMGN) and Synaptics (SYNA) Surge on Jan 31 2015 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Murray Stahl’s $6.4 Billion Horizon Kinetics Sells Out Six Companies in First Quarter May 28 2013 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 08 2011 
ImmunoGen Inc. Reports Operating Results (10-Q) Oct 29 2010 
ImmunoGen Inc. Reports Operating Results (10-K) Aug 27 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Apr 30 2010 

More From Other Websites
ImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : September 22,... Sep 22 2017
ImmunoGen Inc (IMGN): Risks You Need To Consider Before Buying Sep 18 2017
Is ImmunoGen Running Out of Steam, or Taking a Breather? Sep 16 2017
Why Shares of ImmunoGen, Inc. Sank Today Sep 12 2017
Behind Jazz’s Strategic Collaboration with ImmunoGen Sep 07 2017
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Sep 05 2017
Bull of the Day: Jazz Pharmaceuticals (JAZZ) Sep 05 2017
ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due... Sep 01 2017
ETFs with exposure to ImmunoGen, Inc. : August 31, 2017 Aug 31 2017
Biotechs On The Move Aug 31 2017
ImmunoGen (IMGN) Up 17.7% Since Earnings Report: Can It Continue? Aug 31 2017
Featured Company News - Jazz Pharma to Partner with ImmunoGen for the Development and... Aug 31 2017
Why Investors Bid Immunogen Inc. Up Almost 12% Today Aug 30 2017
Harry Boxer’s four biotech stocks to watch Aug 30 2017
Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule Aug 30 2017
ImmunoGen (IMGN) in Focus: Stock Moves 17.3% Higher Aug 30 2017
Today's Research Reports on Stocks to Watch: ImmunoGen, Inc. and Acorda Therapeutics Inc. Aug 30 2017
ImmunoGen and Jazz Enter Into Global Collaboration Aug 29 2017
Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers Aug 29 2017
Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to... Aug 29 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}